GSK's new R&D head bets on genetics with $300 million 23andMe deal

GlaxoSmithKline's new research boss aims to turbo-charge the British group's drug discovery engine with a $300 million bet on genetics by buying a stake in the Silicon Valley gene testing company 23andMe.


from Reuters: Health News https://ift.tt/2uLuoEK
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Teen struggling w/ weight + no support at home, where the hell do I even start?

So I’m a teenager and I’ve been overweight/obese basically my whole life. And it’s been messing with me pretty bad. For the record, I don’...